Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
Information source: Manhattan Eye, Ear & Throat Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Age-Related Macular Degeneration
Intervention: Visudyne (Drug); Kenalog (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Manhattan Eye, Ear & Throat Hospital Official(s) and/or principal investigator(s): Richard F. Spaide, MD, Principal Investigator, Affiliation: Manhattan Eye, Ear & Throat Hospital
Summary
To determine whether VISUDYNE therapy in combination with 4 mg intravitreal triamcinolone
will reduce the average loss from baseline of best corrected visual acuity (BCVA) as
compared with Visudyne therapy without intravitreal triamcinolone at 12 months in subjects
with occult subfoveal and minimally classic subfoveal CNV secondary to AMD. The intravitreal
triamcinolone will be given as either a 1 mg or 4 mg dose. This study will also evaluate the
safety of Visudyne therapy in combination with intravitreal triamcinolone. An interim
statistical readout will be performed when the first 60 patients have completed 6 months of
follow-up evaluation.
Clinical Details
Official title: A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment
Primary outcome: The primary objective of this study is to determine the effect of Visudyne therapy in combination with 4 mg intravitreal triamcinolone on the mean change in BCVA at Month 12.
Secondary outcome: • Proportion of patients having a 15 letter (3 lines) loss or more in BCVA• Proportion of patients having a 15 letter (3 lines) improvement or more in BCVA • Proportion of patients requiring re-treatment at any time during the study • The number of re-treatments required • Difference in treatment effect between 1 mg and 4 mg of triamcinolone acetonide • The change in MNREAD score
Detailed description:
This is a randomized, single-masked (VA examiners, angiographic graders), multi-center,
Phase 2 study with 3 arms comparing VISUDYNE therapy in combination with intravitreal
injection of either a 1 mg or 4 mg of triamcinolone with VISUDYNE therapy without
intravitreal triamcinolone in a 1: 1:1 ratio.
Re-treatment may be administered at 3 month intervals ( 14 days) if evidence of CNV leakage
is detected by fluorescein angiography.
At baseline and at 3 month (+ 14 days) intervals patients will undergo the following
assessments: ophthalmic examination, best corrected visual acuity, fluorescein angiography,
and color fundus photography. The eligibility criteria for inclusion into the study and
re-treatment of patients will be based on fluorescein angiography. Patients receiving
treatment at day-1, week-3, and week-6 following the treatment will have best corrected
ETDRS visual acuity testing and ophthalmic. Those patients not being re-treated will have
will have best corrected ETDRS visual acuity testing and ophthalmic examination at week-6
following the re-treatment evaluation visit.
Adverse events will be assessed throughout the study.
Expected time for recruitment is 6 months; all patients will be followed for the period of
12 months in the study
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- • Age 50 years or older
- Subfoveal CNV secondary to age-related macular degeneration
- Area of the CNV at least 50% of the area of the total neovascular lesion
- The lesion is either minimally classic or occult with no classic
- If the lesion is occult with no classic then subjects must have presumed recent
disease progression in the study eye in the judgment of the Investigator and as
defined by presence of blood associated with the lesion or vision loss or lesion
growth reported or objectively recorded within the preceding 3 months before
randomization to treatment
- Baseline BCVA score between 73 and 19 letters on the ETDRS scale (approximately
20/40 to 20/400)
- Lesion size < 5400 microns
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
- Subjects may not be randomized to treatment if they:
1. Have evidence of predominantly classic CNV, clinically significant intraocular
inflammation, angioid streaks, presumed ocular histoplasmosis syndrome, axial
myopia greater than –6 diopters, or other precursors of choroidal
neovascularization
2. Have additional eye disease that compromises the visual acuity of the study eye.
3. Are receiving or require chronic concomitant therapy with systemic or topical
ocular corticosteroids or NSAIDS. Chronic concomitant therapy is defined as
multiple doses taken daily for 3 or more consecutive days at any time during the
course of the 12-month study). A low dose (up to 100 mg po qd) of aspirin (ASA)
taken for prophylaxis of MI and/or stroke is permitted during the study.
4. Are using coumadin.
5. Have known hypersensitivity to verteporfin or triamcinolone
6. Have CNV that does not involve the geometric center of the foveal avascular
zone, as determined by color photography and fluorescein angiography
7. Are unable to be photographed to document CNV, e. g. due to media opacity,
allergy to fluorescein dye or lack of venous access
8. Have lens opacities which, in the investigator’s opinion, would progress during
the course of the study and would affect central vision in the study eye. Such
cataracts may be removed at least 2 months before entering the subject in the
study
9. Have a history of treatment for CNV, other than confluent laser
photocoagulation, in the study eye (e. g., PDT, submacular surgery, radiotherapy
or macular scatter “grid” laser photocoagulation
10. Are participating in another clinical trial requiring follow-up examinations or
are receiving or have received any experimental treatment for CNV or any other
investigational new drug within 12 weeks prior to the start of study treatment
11. Have an intraocular pressure greater than 21 mm Hg on or off medication on entry
to the study.
12. Have received prior treatment with another anti-angiogenic compound (e. g.,
Sandostatin®, LY333531, Macugen, RhuFab, etc.) within 6 months prior to
screening
13. Are unwilling or unable to follow or comply with all study-related procedures.
Locations and Contacts
Vh/UBC Eye Care Centre, Vancouver, British Columbia V5Z 3N9, Canada
Manhattan Eye, Ear & Throat Hospital, New York, New York 10021, United States
Additional Information
Starting date: October 2003
Last updated: July 11, 2007
|